Ranking · Winter 2023 · Healthcare · Drug Discovery and Delivery

Invitris

Creating new protein-based drugs at scale

4.0%

odds of being acquired in the next two years

0.6× the average (6.8%)

#4059 of 4,339 active YC companies · top 95%

Team of 6 · Munich, BY, Germany

Raises the odds

↑ team of 6–10

↑ based in Remote

Lowers the odds

↓ industry: Healthcare

↓ “scale” in its one-liner

↓ tag: Biotech

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Invitris's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

invitris.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub